Novartis says lung cancer drug canakinumab fails another trial

[August 15, 2022]  ZURICH (Reuters) -Novartis said on Monday its canakinumab drug to help treat non-small cell lung cancer failed a phase III trial, the latest blow for the treatment which also fell short in a study last year.

The drug, used as an adjuvant treatment, did not meet its primary endpoint of disease-free survival, the Swiss company said.

Adjuvant treatments are additional cancer treatments after the primary one intended to lower the risk the cancer will return.

The failure in the latest trial, called Canopy A, is a setback for Novartis after canakinumab failed in a separate study last year where it was tried in combination with another drug and chemotherapy.

A sign marks the Novartis Institutes for BioMedical Research facility in Cambridge, Massachusetts, U.S., June 16, 2021. REUTERS/Brian Snyder/File Photo

"Consensus expectations for this high-risk project remained zero or low with the remaining market exclusivity for canakinumab limited until 2028," said Zuercher Kantonalbank analyst Laurent Flamme.

He estimated annual sales of around 300 million Swiss francs ($317.9 million)by 2026 for the drug as an adjuvant treatment for non-small cell lung cancer.

($1 = 0.9436 Swiss francs)

(Reporting by John Revill; Editing by Christian Schmollinger and Emelia Sithole-Matarise)

[© 2022 Thomson Reuters. All rights reserved.]  This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.